Regional effects of MK-801 on dopamine release: Effects of competitive NMDA or 5-HT2A receptor blockade

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 3, 1996, Pages 1541-1549

  Schmidt, Christopher J ^a   Fadayel, Gina M ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 (3 PHOSPHONOPROPYL) 2 PIPERAZINECARBOXYLIC ACID; 4 AMINOBUTYRIC ACID; 4 OXO 5 PHOSPHONONORVALINE; 4 PHOSPHONOMETHYLPIPECOLIC ACID; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; DIZOCILPINE; DOPAMINE; HOMOVANILLIC ACID; MDL 100453; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; POLYSORBATE 80; SEROTONIN 2A ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG EFFECT; DRUG SELECTIVITY; FOREBRAIN; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CORPUS STRIATUM; DIZOCILPINE MALEATE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PROSENCEPHALON; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, SEROTONIN;

EID: 0030438479     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40: 399-412, 1991.
2. BRISTOW, L. J., HUTSON, P. H., THORN, L. AND TRICKLEBANK, M. D.: The glycine/ NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents. Br. J. Pharmacol. 108: 1156-1163, 1993.
3. BUBSER, M., KESEBERG, U., NOTZ, P. K. AND SCHMIDT, W. J.: Differential behavioral and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats. Eur. J. Pharmacol. 229: 75-82, 1992.
4. BULLER, A. L., LARSON, H. C., SCHNEIDER, B., BEATON, J. A., MORRISETT, R. A. AND MONAGHAN, D. T.: The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition. J. Neurosci. 14: 5471-5484, 1994.
5. CARLSSON, M. L.: Are the disparate pharmacological profiles of competitive and un-competitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways? J. Neural Trans. 94: 1-10, 1993.
6. CARLSSON, M. L. AND CARLSSON, A.: The NMDA antagonist, MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Trans. 75: 221-226, 1989.
7. 2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse - implications for psychosis, J. Neural Trans. 100: 225-237, 1995.
8. CLINESCHMIDT, B. V., WILLIAMS, M., WITOSLAWSKI, J. J., BUNTING, P. R., RISLEY, E. A. AND TATARO, J. A.: Restoration of shock-suppressed behavior by treatment with (+)-5-methyl-10, 11-dihydro-5H-dibenzo[a, d]cyclohepten-5, 10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev. Res. 2: 147-163, 1982.
9. GRISWELL, H. E., JOHNSON, K. B., MUELLER, R. A. AND BREESE, G. R.: Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D- aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. J. Pharmacol. Exp. Ther. 265:1001-1010, 1993.
10. DEUTCH, A. Y., TAM, S-Y., FREEDMAN, A. S., BOWERS, M. B. AND ROTH, R. H.: Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response. Eur. J. Pharmacol. 134: 257-264, 1987.
11. DRAY, A., DAVIES, J., OAKLEY, N. R., TONGROACH, P. AND VELLUCCI, S.: The dorsal and median raphe projections to the substantia nigra in the rat: electrophysiological, biochemical and behavioral observations. Brain Res. 151: 431-442, 1978.
12. FREEMAN, A. S. AND BUNNEY, B. S.: The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. Eur J. Pharamcol. 104: 287-293, 1984.
13. FRENCH, E. D.: Effects of phencyclidine on ventral tegmental A10 dopamine neurons in the rat. Neuropharmacol. 25: 241-248, 1986.
14. FRENCH, E. D. LEVENSON S. AND CECI, A.: Characterization of the actions of phencyclidine on midbrain dopamine neurons. NIDA Res. Monograph 95: 255-263, 1990.
15. FRENCH, E. D., FERKANY, J., ABREU, M. AND LEVENSON, S.: Effects of competitive N-methyl-D-aspartate antagonists on midbrain dopamine neurons: an electrophysiological and behavioral comparison to phencyclidine. Neuropharmacol. 30: 1039-1046, 1991.
16. FRENCH, E. D.: Competitive NMDA receptor antagonists attenuate phencyclidine-induced excitation of AlO dopamine neurons. Eur. J. Pharmacol. 271: 1-7, 1992.
17. FRENCH, E. D., MURA, A. AND WANG, T.: MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat AlO dopamine neurons: comparison to competitive NMDA antagonists. Synapse 13: 108-116, 1993.
18. FRENCH, E. D. AND CECI, A.: Non-competitive N-methyl-D-aspartate antagonists are potent activators of ventral tegmental AlO dopamine neurons. Neurosci. Lett. 119: 159-162, 1990.
19. HANSSON, L. O., WATER, N., WINBLAD, B., GOTTFRIES, C-G. AND CARLSSON, A.: Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue. J. Neural. Trans. 98: 217-235, 1994.
20. HOFFMAN, D. C.: Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural. Trans. 89: 1-10, 1992.
21. HOLLMAN, M., BOULTER, J., MARON, C., BEASLEY, L., SULLIVAN, J., PECHT, G. AND HEINEMANN, S.: Zinc potentiates agonist-induced currents at certain splice variants of the NMDA receptor. Neuron. 10: 943-954, 1993.
22. HONDO, H., YONEZAWA, Y., NAKAHARA, T., NAKAMURA, K., HIRANO, M., UCHIMUARA, H. AND TASHIRO, N.: Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Res. 633: 337-342, 1994.
23. IMPERATO, A., SCROCCO, M. G., BACCHI, S. AND ANGELUCCI, L.: NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur. J. Pharmacol. 187: 555-556, 1990.
24. JAVITT, D. C. AND ZUKIN, S. R.: Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148: 1301-1308, 1991.
25. KASHIHARA, K., HAMAMURA, T., OKUMURA, K. AND OTSUKI, S.: Effect of MK-801 on endogenous dopamine release in vivo. Brain Res. 528: 80-82, 1990.
26. KEEFE, K. A., ZIGMOND, M. J. AND ABERCROMBIE, E. D.: In vivo regulation of extracellular dopamine in the neostriatum: influence of impulse activity and local excitatory amino acid release. J. Neural Trans. 91: 223-240, 1993.
27. KLOOG, Y., HARING, R. AND SOKOLOVSKY, M.: Kinetic characterization of the phencyclidine-N-methyl-D-aspartate receptor interaction: evidence for a steric blockade of the channel. Biochem. 27: 843-848, 1988a.
28. 3H]dibenzocycloalkenimine (MK-801) to the N-methyl-D-aspartate (NMDA) receptor and its therapeutic implications. FEBS Lett. 230: 167-170, 1988b.
29. LILJEQUIST, S., OSSOSKA, K., GRABOWSKA-ANDEN, M. AND ANDEN, N.: Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and the metabolism of dopamine in various brain areas of mice. Eur. J. Pharmacol. 195: 55-61, 1991.
30. LILLRANK, S. M., O'CONNOR W. T., OJA, S. S. AND UNGERSTEDT, U.: Systemic phencyclidine administration is associated with increased dopamine, GABA, and 5-HIAA levels in the dorsolateral striatum of conscious rats: an in vivo microdialysis study. J. Neural Trans. 95: 145-155, 1994.
31. LOSCHER, W., ANNIES, R. AND HONACK, D.: The N-methyl-D-aspartate receptor antagonist MK-801 induced increase in dopamine and serotonin metabolism in several brain regions of rats. Neurosci. Lett. 128: 191-194, 1991.
32. LOSCHER, W. AND HONACK, D.: The behavioral effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. Eur. J. Pharmacol. 215: 199-208, 1992.
33. 2A receptor antagonist. Eur. J. Pharmacol. 259: 137-141, 1994.
34. 2A receptors. Eur. J. Pharmacol. 280: R9-R11, 1995.
35. MILLER, D. W. AND ABERCROMBIE, E. D.: Basal ganglia substrates of MK-801-induced stimulation of striatal dopamine release. Abst. Soc. Neurosci. 20: 1558, 1994.
36. 3H]MK-801 binding to subpopulations of NMDA receptors. Neurosci. Lett. 122: 21-24, 1991.
37. MONYER, H., BURNASHEV, N., LAURIE, D. J., SAKMANN, B. AND SEEBERG, P. H.: Developmental and regional expression in the rat brain and function properties of four NMDA receptors. Neuron. 12: 529-540, 1994.
38. MURASE, S., MATHE, J. M., GRENHOFF, J. AND SVENSSON, T. H.: Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential action on firing pattern related to anatomical localization. J. Neural. Trans. 91: 13-25, 1993.
39. 2) receptor mediated enhancement of cortical unit activity. J. Physiol. Pharmacol. 70: 1604-1609, 1992.
40. NORTH, R. A. AND UCHIMURA, N.: 5-Hydroxytryptamine acts at 5-HT2 receptors to decrease potassium conductance in rat nucleus accumbens neurons. J. Physiol. 417: 1-12, 1989.
41. OUAGAZZAL, A., NIEOULLON, A. AND AMALRIC, M.: Effects of dopamine D1 and D2 receptor blockade on MK-801-induced hyperlocomotion in rats. Psychopharmacol. 111: 427-434, 1993.
42. OUAGAZZAL, A., NIEOULLON, A. AND AMALRIC, M.: Locomotor activation induced by MK-801 in the rat: postsynaptic interactions with dopamine receptors in the ventral striatum. Eur. J. Pharacol. 251: 229-236, 1994.
43. 3 mediated control of dopaminergic function. Psychopharmacol. 112: S60-67, 1993.
44. PIQUET, P. AND GALVIN, M.: Transient and long-lasting actions of 5-HT on rat dentate gyrus neurons in vitro. J. Physiol. (Lond) 481: 629-639, 1994.
45. 2 receptors facilitates depolarization of neocortical neurons by N-methyl-D-aspartate. Eur. J. Pharmacol. 231: 347-354, 1993.
46. RASMUSSEN, K. AND AGHAJANIAN, G. K.: Serotonin excitation of facial motoneurons: receptor subtype characterization. Synapse 5: 324-332, 1990.
47. RAO, T. S., KIM, H. S., LEHMAN, J., MARTIN, L. L. AND WOOD, P.: Differential effects of phencyclidine (PCP) and ketamine on mesocortical and mesostriatal dopamine release in vivo. Life Sci. 45: 1065-1072, 1989.
48. 3H]MK-801 binding in rat brain. J. Neurochem. 60: 1344-1353, 1993.
49. 2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methyl-enedioxymethamphetamine. Eur. J. Pharmacol. 223: 65-74, 1992.
50. 2 receptors in schizophrenia and antipsychotic activity. International Clinical Psychopharmacol. 8: Suppl. 2, 25-32, 1993.
51. 2A antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur. J. Pharmacol. 273: 273-279, 1995.
52. 2A receptors in antipsychotic activity. Life Sci. 56: 2209-2222, 1995.
53. 1A agonists. J. Pharmacol. Exp. Ther. 273: 101-112, 1995.
54. SHARP, T., ZETTERSTROM, T. AND UNGERSTEDT, U.: An in vivo study of dopamine release and metabolism in rat brain regions using intracerebral dialysis. J. Neurochem. 47: 113-122, 1986.
55. 2A antagonist MDL 100,907 blocks dizocilpine-induced increases in the firing rate of A10 dopaminergic neurons. Schizophrenia Research 15(1,2): 21, 1995.
56. 2 receptor antagonist, MDL 100,907, as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies J. Pharmacol Exp. Ther. 266: 684-691, 1993.
57. STANDAERT, D. G., TESTA, O. M., YOUNG, A. B. AND PENNEY, J. B.: Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J. Comp. Neurol. 343: 1-16, 1994.
58. STEINFELS, G. F., TAM, S. W. AND COOK, L.: Electrophysiological effects of selective σ-receptor agonists, antagonists and the selective phencyclidine receptor agonist, MK-801 on midbrain dopamine neurons. Neuropharmacol. 2: 201-208, 1989.
59. VEZZANI, A., SERAFINI, R., STASI, M. A., CACCIA, S., CONRI, I., TRIDICO, R. V. AND SAMANIN, R.: Kinetics of MK-801 and its effects on quinolinic acid-induced seizures and neurotoxicity in rats. J. Pharmacol. Exp. Ther. 249: 278-283, 1989.
60. WANG, J. AND JOHNSON, K. M.: Arcaine and magnesium inhibition of the NMDA receptor ionophore complex: evidence for distinct voltage dependent sites. Can. J. Physiol. Pharmacol. 70: 283-288, 1992.
61. WATERS, N., CARLSSON, A. AND HANSSON L.: An animal model of schizophrenia based on multivariate analysis of monoaminergic biochemistry and behavior. Abst. Soc. Neurosci. 20: 825, 1994.
62. WEDZONY, K., KLIMEK, V. AND GOLEMBIOWSKA, K.: MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors. Brain Res. 622: 325-329, 1993.
63. WEIHMULLER, F. B., O'DELL, S. J., COLE, B. N. AND MARSHAL, J. F.: MK-801 attenuates the dopamine releasing but not the behavioral effects of methamphetamine: an in vivo microdialysis study. Brain Res. 549: 230-235, 1991.
64. WHITTEN, J. P., BARON, B. M., MUENCH, D., MILLER, F., WHITE, H. S. AND MCDONALD, I. A.: (R)-4-oxo-5-phosphononorvaline: a new competitive glutamate antagonist at the NMDA receptor complex. J. Med. Chem. 33: 2961-2963, 1990.
65. WHITTON, P. S., BIGGS, C. S., PEARCE, B. R. AND FOWLER, L. J.: Regional effects of MK-801 on dopamine and its metabolites studied by in vivo microdialysis. Neurosci. Lett. 142: 5-8, 1990a.
66. WHITTON, P. S., BIGGS, C. S., PEARCE, B. R. AND FOWLER, L. J.: MK-801 increases extracellular 5-hydroxytryptamine in rat hippocampus and striatum in vivo. J. Neurochem. 58: 1573-1575, 1992b.
67. WOLF, M. E., WHITE, F. J. AND HU, X.-T.: Behavioral sensitization to MK-801 (dizocilpine): neurochemical and electrophysiological correlates in the mesoaccumbens dopamine system. Behav. Pharmacol. 4: 429-442, 1993.
68. ZHANG, J., CHIODO, L. A. AND FREEMAN, A. S.: Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons. Brain Res. 590: 153-163, 1992.
69. ZHANG, J., CHIODO, L. A. AND FREEMAN, A. S.: Influence of excitatory amino acid receptor subtypes on the electrophysiological activity of dopaminergic and nondopaminergic neurons in rat substantia nigra. J. Pharmacol. Exp. Ther. 269: 313-321, 1994.
70. ZHANG, J., CHIODO, L. A. AND FREEMAN, A. S.: Effects of phencyclidine, MK-801 and 1,3-di(2-tolyl)guanidine on non-dopaminergic midbrain neurons. Eur. J. Pharmacol. 230: 371-374, 1993.